<DOC>
	<DOCNO>NCT01852149</DOCNO>
	<brief_summary>The purpose study assess safety feasibility Mitralign Percutaneous Annuloplasty System humans treatment chronic functional mitral regurgitation . No formal test hypothesis propose trial .</brief_summary>
	<brief_title>Mitralign Percutaneous Annuloplasty First Man Study</brief_title>
	<detailed_description>The primary objective study test ability safely perform mitral posterior annulus plication Mitralign System eligible patient chronic functional MR use endovascular approach . Data obtain study , combine extensive pre-clinical data , provide important technical early clinical outcome information drive next phase clinical investigation potentially enhance future design Mitralign Percutaneous Annuloplasty System . It anticipate Mitralign System one day provide physician safe effective alternative therapy treat patient candidate mitral valve repair offer primary therapy option patient superior current treatment modality . This single-arm , multi-center , prospective study design test safety feasibility MPAS treat patient chronic , functional MR perform plication posterior mitral annulus . Up total 36 patient chronic functional mitral regurgitation enrol : 1 . ) Up 16 patient ( 12 patient + 1 roll-in patient per site ) enrol Phase I . Up thirty-four ( 34 ) patient enrol Phase II ( MITRALIGN ADVANTAGE ) . All patient follow 24 month . Up 5 site Europe South America participate . Study procedure include implantation MPAS , Trans-Esophogeal Echo , Trans-Thoracic Echo , Blood test , 6-min walk , Quality Life , Chest X-ray ECG . Descriptive Statistics conduct study .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Patient chronic functional mitral regurgitation . Patient great 18 year old . Documented symptom CHF NYHA IIIV . Left ventricular ejection fraction 30 60 percent . Acceptable candidate cardiac surgery and/or blood transfusion . Patient legal guardian understands study requirement treatment procedure provide write Informed Consent study specific test procedure perform . Willing comply specify followup evaluation . Mitral regurgitation grade 2 . Patient mitral plane apex dimension 5 cm . Structurally normal mitral valve . Patient significant organic mitral valve pathology myxomatous degeneration , mitral valve prolapse flail leaflet moderate severe valve calcification , rupture papillary muscle rupture chordae tendinae . Previous mitral valve repair mitral valve replacement . Patient mitral stenosis . Patient moderate severe aortic stenosis moderate severe aortic regurgitation . Patient endocarditis . MI within 30 day prior index procedure . Unstable angina . Percutaneous Coronary Intervention within 30 day prior index procedure . CABG within 3 month prior index procedure . Planned PCI le 30 day post index procedure . Planned CABG within 6 month post index procedure . Patient severe , multivessel coronary artery disease tolerate sudden hemodynamic change acute hemoglobin drop . Cardiogenic Shock characterize systolic pressure le 80 mm Hg central filling pressure great 20 mm Hg , cardiac index less 1.8 liter per minute per m2 intraaortic balloon pump intravenous inotropes need maintain systolic pressure great 80 mm Hg cardiac index great 1.8 liter per minute per m2 . Patient peripheral vascular disease tortuousity would prevent percutaneous access 14 Fr introducer sheath intervention Mitralign system . Cerebrovascular Accident within past 6 month . Acute chronic renal dysfunction creatinine great 2.0mg per dl 177Âµmolper dl Anemia Hb great 10 g per dl . Thrombocytopenia platelet count le 100,000 per mm3 ) thrombocytosis platelet great 750,000 per mm3 ) . Bleeding disorder hypercoaguable state . Active peptic ulcer active gastrointestinal bleeding . Contraindication therapy antiplatelet anticoagulant drug . Contraindications patient 's refusal blood transfusion . Known allergy stainless steel platinum iridium polyester . Any prior true anaphylactic reaction contrast agent define know anaphylactoid nonanaphylactic allergic reaction contrast agent adequately premedicated prior index procedure . Pregnancy female childbearing potential positive pregnancy test within 24 hour index procedure undergo angiography xray , lactate . Comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study . Life expectancy le 24 month due medical condition . Currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study . Patient impaired judgment . Patient undergo emergency treatment . Thrombus leave ventricle leave atrium . Echocardiographic evidence congenital , pericardial infiltrative heart disease . Suboptimal echocardiographic ( TTE ) windows , lead incomplete quantification FMR anatomic assessment . Significant subvalvular trabecularization , muscle bridge pocket</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Mitral Valve Regurgitation</keyword>
	<keyword>Coaptation</keyword>
	<keyword>Mitral Valve Repair</keyword>
	<keyword>Plication</keyword>
	<keyword>Leaflet</keyword>
	<keyword>Annulus</keyword>
	<keyword>Mitral Annuloplasty</keyword>
</DOC>